Skye Bioscience (SKYE) Change in Cash (2012 - 2026)
Skye Bioscience (SKYE) posted quarterly Change in Cash of $2.3 million for Q1 2026, up 110.3% year-over-year from $1.1 million in Q1 2025, and up 118.05% quarter-over-quarter from -$12.6 million in Q4 2025.
Skye Bioscience (SKYE) Change in Cash (2012 - 2026) Analysis & Trends
Skye Bioscience (SKYE) has reported Change in Cash for 15 consecutive years, with $2.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Cash rose 110.3% year-over-year to $2.3 million; the TTM figure through Mar 2026 stood at -$38.3 million (up 16.8% YoY), while the FY2025 annual figure was -$62.5 million, down 207.67% from the prior year.
- Change in Cash improved to $2.3 million in Q1 2026 per SKYE's latest filing, from -$12.6 million in the prior quarter.
- Across five years, Change in Cash topped out at $82.1 million in Q1 2024 and bottomed at -$22.6 million in Q2 2025.
- Historically, Change in Cash has averaged -$49327.2 across 5 years, with a median of -$3.1 million in 2022.
- Annual changes were most pronounced in 2022 — Change in Cash tumbled 9174.48% — and 2024, when it soared 5663.79%.
- Skye Bioscience's Change in Cash stood at $829144.0 in 2022, then plunged by 567.28% to -$3.9 million in 2023, then slumped by 108.47% to -$8.1 million in 2024, then slumped by 55.48% to -$12.6 million in 2025, then surged by 118.05% to $2.3 million in 2026.
- Business Quant data shows SKYE's Change in Cash at $2.3 million in Q1 2026, -$12.6 million in Q4 2025, and -$5.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Cash (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 649.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -504.60 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -185.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 427.25 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -2.94 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -37.42 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 225.59 Mn |
| 10 | Skye Bioscience | 10.86 Mn | 10.86 Mn | - | -80,658.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.27 Mn |
| Dec 31, 2025 | -12.56 Mn |
| Sep 30, 2025 | -5.40 Mn |
| Jun 30, 2025 | -22.58 Mn |
| Mar 31, 2025 | -21.99 Mn |
| Dec 31, 2024 | -8.08 Mn |
| Sep 30, 2024 | -6.71 Mn |
| Jun 30, 2024 | -9.22 Mn |
| Mar 31, 2024 | 82.09 Mn |
| Dec 31, 2023 | -3.87 Mn |
| Sep 30, 2023 | 13.65 Mn |
| Jun 30, 2023 | -2.12 Mn |
| Mar 31, 2023 | 1.42 Mn |
| Dec 31, 2022 | 829,144.00 |
| Sep 30, 2022 | -2.51 Mn |
| Jun 30, 2022 | -3.08 Mn |
| Mar 31, 2022 | -2.98 Mn |
| Dec 31, 2021 | -2.11 Mn |
| Sep 30, 2021 | 5.90 Mn |
| Jun 30, 2021 | 33,908.00 |